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 Endothelial cells exist in a state of dynamic stability allowing for a balance 
between quiescence and response. These cells create the barrier system of the vasculature 
as well as drive the growth of new vessels. The disease Cerebral Cavernous 
Malformation (CCM) disrupts both processes and is characterized by leaky, cavernous 
vascular lesions in the CNS, resulting in headache, seizure, and stroke. CCM occurs in 
both a sporadic and familial form thought to follow the Knudsen two-hit model of 
retinoblastoma. Studies have been primarily focused on late stage disease, leaving little 
understanding of the earliest stages and the precise role of the second hit. We sought to 
study early developmental onset to identify morphological characteristics that could 
provide mechanistic insight to the key initiating factors.   
 We generated an inducible endothelial knockout mouse model of CCM and found 
that when the second hit occurs at birth, mice develop cavernous malformations in the 
brain and the retina. We determined that lesions arise in a spatially and temporally 
predictable pattern in a limited developmental window. We further showed vessel defects 
are preceded by endothelial hypersprouting and an impaired cellular response to flow. In 
the context of CCM, this suggests that an inability of cells to react to their environment 
could result in lesion development. Our findings that loss of the second hit in adulthood  
was insufficient to cause disease, combined with the predictable nature of development, 
  
iv 
 suggested that environmental factors may be necessary contributors to disease onset. 
While loss of the genetic hits in adulthood was not enough to cause disease we found 
that, when combined with localized vascular endothelial growth factor (VEGF), lesions 
can arise.  
 Changes in the surrounding tissue environment can be caused by disrupted barrier 
functions, promoting a disease state like that seen in CCM. In our pursuit to further 
understand barrier function in the face of environmental challenges, we defined the novel 
process of endothelial extrusion. Extrusion is the removal of an apoptotic cell from a 
monolayer, prior to its structural collapse, via contraction of an actin ring. Together these 
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 The vascular system spans the entire body as a vast, branching network that 
pervades most tissues. This network is comprised of interconnected large arteries and 
veins, which expand into arterioles and venoules and finally extend into labyrinths of 
small capillaries.  Each blood vessel is comprised of layers of connective tissue, support 
cells, and endothelial cells (Figure 1.1). The thickness of each layer reflects the function 
of the vessel. For example, arteries are large, central vessels that transport ample volumes 
of blood under high pressure.  As such, arteries have more support cells and connective 
tissue.  In contrast, capillaries operate under lower pressure in a diffuse network; 
therefore the amount of support cells and connective tissue needed is much less. 
Regardless of vessel function however, the inner lining of endothelial cells is always 
present (1, 2).  
 In capillaries, the endothelial lining exists in a monolayer.  Despite its single-cell 
thickness, this monolayer is responsible for several processes of vascular biology.  It is in 
the capillary beds that endothelial cells enact their role as gatekeepers of the blood-tissue 
barrier and allow for the selective passage of matter such as nutrients and oxygen (3). 
These cells join together via several junction contacts between one another. One of the 
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most well characterized junction proteins is Vascular Endothelial Cadherin, VE-
Cadheren, which plays an essential role in establishing and maintaining the endothelial 
barrier.  Increasing or decreasing levels of VE-Cadherin between the cells can increase or 
decrease the strength of the endothelial barrier, respectively (4).  In addition to joining 
with each other, endothelial cells are connected to the basement membrane via 
transmembrane adhesion molecules known as integrins. The basement membrane is a 
laminin-rich matrix that provides additional support and organization for the endothelial 
cells (5). An established endothelial monolayer can then act as a platform for new 
vascular growth via the process of angiogenesis 
 Angiogenesis is the creation of new vessels and begins when an endothelial cell 
responds to growth factors produced by the nearby tissue microenvironment. The 
responding cell, referred to as a tip cell, becomes migratory and begins to extend sprouts. 
The tip cell then signals to its neighbors, inducing them to become support cells that will 
form the endothelial network trailing behind the tip cell.  These support cells, referred to 
as stalk cells, proliferate, lumenize, and aid in recruiting vascular smooth cells in order to 
generate the new vascular network (6-8).  
 Once the vascular network has been established, the endothelial cells enter into a 
state of quiescience and go on to execute their role in barrier function. This barrier of 
endothelial cells selectively allows for the passage of nutrients, cells, and fluid while 
maintaining the structural integrity of the separate tissue compartments.   
 Dysfunction within the endothelium has been attributed to several diseases of the 
vasculature. For example, a disruption in appropriate VE-Cadherin signaling and junction 
localization can result in a less effective barrier. This may contribute to the formation of 
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rheumatoid arthritis by increasing vascular permeability within synovial joints, allowing 
fluid and inflammatory cells to leak into the tissue (9). Another example of endothelial 
dysfunction and disease can be seen with the disruption of angiogenic regulation in 
diabetic retinopathy. In this disease, inappropriate growth factor secretion and response 
by the endothelial cells results in inappropriate neovascularization within the retina (10). 
Different types of endothelial dysfunction will subsequently lead to different disease 
states, often involving crossover of many endothelial signaling pathways. One prominent 
example of vascular disease involving dysregulation of both barrier function and 
angiogenesis is vascular malformations.   
 Vascular malformations are defects in normal vascular structure. Healthy vascular 
structure is one of ordered, sequential vascular branches that form organized networks of 
lumenized vessels allowing for proper blood flow and transport. In the case of vascular 
malformations, the architecture is disrupted such that select areas develop into tortuous, 
dilated entaglements of improperly lumenized vessels.  There are several different types 
of vascular malformations, each with their own unique architecture and endothelial 
defects. These include arteriovenous malformations, telangectasias, venous 
malformations, and cavernous hemangiomas (11). The presence of cavernous 
hemangiomas is the hallmark of the disease Cerebral Cavernous Malformation (CCM) 
(Figure 1.2). The vascular malformations that develop in CCM primarily arise in the 
brain and are characterized by clusters of vascular caverns that lack any intervening brain 
parenchyma, giving them a raspberry-like structure (12).  The lesions themselves, thought 
to be of capillary origin, are comprised of a thin-walled layer of endothelium that lacks 
smooth muscle support and is surrounded by fibrosis. Blood can fill into the caverns and, 
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due to the compromised structure and inherent endothelial dysfunction, can leak into the 
surrounding brain tissue. This can lead to headaches, seizure, and stroke for those with 
the disease (13). CCM affects 0.5% of the population and can occur sporadically or can 
be inherited in an autosomal dominant pattern. The inherited form of the disease is 
caused by the loss of function in one of three genes: CCM1, CCM2, and CCM3 (14-16). 
 Each of these proteins is thought to act as a scaffold, and all have been shown to 
bind together in a complex and can interact with several other unique signaling partners. 
None of the proteins are known to have enzymatic activity (17). CCM1, also known as 
Krev interaction trapped protein 1 (Krit1), was first identitified in a yeast-two hybrid 
screen for Rap1 effectors. Rap1 binding to CCM1 stabilizes VE-Cadherin at the cell 
junctions (18). Without CCM1, these junctions become disorganized (19).  Additional 
consequences of loss of CCM1 include activation of β1-integrin, dysregulation of Notch 
signaling, and increased levels of reactive oxygen species, implying a complex role for 
this gene in cell signaling (17). A recent report identified the TGF-β pathway as a major 
player in pathogenesis in the absence of CCM1.  The subsequent increase in TGF-β and 
BMP6 induced endothelial to mesenchymal transition in brain endothelial cells, 
contributing to the formation of vascular malformations (20). In addition to these 
signaling roles, CCM1 is important in cytoskeletal dynamics much like CCM2 (21).  
 At first known as osmosensing scaffold for MEKK3 (OSM), CCM2, was 
originally identified in a yeast-2-hybrid screen for MEKK3 binding partners. Upon stress 
signaling, CCM2 activates various mitogen activating protein kinases (MAPKs) such as 
p38 and JNK (22). CCM2 can also activate the Rho GTPases and has been shown to bind 
to RhoA. In the absence of  CCM2, cells upregulate the activity of RhoA leading to the 
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formation of intracellular actin stress fibers (21). These stress fibers disrupt normal cell 
morphology, which in turn leads to a decrease in endothelial barrier function (23).  
 In contrast to both CCM1 and CCM2, CCM3 has not been implicated in the 
activity of RhoA. CCM3, known also as programmed cell death 10 (PDCD10), was 
identified for its role in apoptosis of cultured premyeloid cells. Endothelial cells lacking 
CCM3 do not exhibit the same cytoskeletal defects a seen in cells missing CCM1 or 
CCM2 (24). Instead, CCM3 is required for appropriate establishment of golgi polarity, 
dependent upon the binding of PDCD10 to the proteins in the germinal center kinase 
(GCK) family (17) (Table 1). 
 Despite the apparent different biochemical functions of these three proteins, 
mutations in any one of their encoding genes results in phenotypically similar disease 
states, suggesting that a common convergent mechanism is at play (24). While the 
sporadic form of the disease gives rise to singular lesions and progresses at a slow rate, 
the inherited form of the disease is more aggressive, usually presenting with multiple 
lesions that progress rapidly. This disease pattern resembles that seen in the rare cancer, 
retinoblastoma.  Retinoblastoma also occurs in a sporadic and inherited form, with the 
inherited form being much more severe.  Alfred Knudson in 1971 made the proposition 
that, based on clinical data, multiple  “hits” to normal cellular function were required to 
induce disease.  In familial disease, the first hit is the inherited mutation, and acquisition 
of the second hit would rapidly lead to cancer. The sporadic form, however, would 
require two somatic hits (25). This type of mechanism is known as the Knudson two-hit 
hypothesis, and evidence from CCM patients support a similar mechanism to explain 
CCM. Surgically excised tissue from patients with familial CCM were shown to contain 
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not only their inherited, germline mutation, but an additional mutation in the other CCM 
allele, implying that endothelial cells within CCM lesions had acquired a second genetic 
hit much as Knudson proposed (26, 27).  
 In order to study the pathogenesis of CCM and whether the two-hit model applies, 
numerous mouse models have been generated.  Initial models included creating germline 
knockouts for the CCM genes. Mice homozygous for any of a deleted CCM allele failed 
to survive past embryonic development, while mice that were heterozygous went on to 
survive through adulthood with no apparent vascular defects (21, 28, 29). These initial 
models, while supportive of the hypothesis that loss of heterozygosity was needed for 
CCM disease, were not ideal for disease study.  While the death of the germline 
homozygous knockouts was attributed to failed vascular development, these mice were 
insufficient to address whether the loss of CCM led to brain lesion formation or how the 
two-hit model might be at play. Therefore additional models needed to be created that 
allowed for mice to survive beyond birth. The first model took advantage of the 
heterozygous CCM1 loss of function mouse that was also homozygous for a mutation in 
p53. While mice heterozygous for CCM1 do not form any sort of vascular anomalies, the 
homozygosity at p53 promotes genetic instability, increasing the mutation rate and thus 
increasing the chance of the loss of the second CCM1 allele.  These mice did go on to 
develop CCM lesions (30). A similar approach was conducted by McDonald et al. using a 
mismatch repair deficient mouse, Msh2, in lieu of the p53 mutant mouse.  Similar results 
were obtained for CCM1; however, when done with CCM2, mice failed to develop any 
type of lesion (31). While these models provided interesting insight and supported the 
two-hit hypothesis, these models were not fully penetrant, and only a subset of the 
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populations developed malformations. In addition, the inherent genetic instability of the 
models led to the development of other non-CCM mutations as well as to the 
development of tumors. Both of these factors skew the ability to test the specific role that 
loss of the CCM genes play in disease. 
 An alternative method, less reliant on serendipitous genetic modification, has 
been employed by a number of laboratories.  This approach takes advantage of an 
inducible transgene encoding the Cre recombinase to mutate the second CCM allele at a 
time and in tissues determined by the investigator (20, 24, 29). These Cre models allowed 
for a more reliable induction of disease that faithfully recapitulated human disease 
progression and anatomical pathology (24). 
 Such models have allowed a more detailed exploration into cellular mechanisms 
disrupted following the second genetic hit and offer hope for the development of 
pathway-specific therapeutics. A recent report using an inducible model of CCM1 
implicated the TGF-β pathway in disease progression and has prompted attempts to treat 
CCM disease with TGF-β inhibitors. While moderately effective, the treatment did not 
completely rescue the disease phenotype, and lesions still developed (20). Another study, 
spurred by a mouse model of CCM2 disease, tested the efficacy of the Rho inhibitor 
Fasudil, but it resulted in limited success (32). Despite the moderate promise seen with 
these drugs, it highlights a critical limited focus of current CCM research. Such research 
is primarily focused on late stage disease, after lesions have been well established. While 
this has yielded exciting results via the identification of novel pathways, it raises the risk 
of confusion between primary effects and secondary effects associated with the extended 
disease process.  Signal cascades that are disrupted in mature disease states may not be 
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those responsible for its onset, raising the likelihood of drugs developed to a symptom 
and not the cause. Understanding how this two-hit mechanism impacts vascular 
development and the early pathophysiology of the disease would allow for identification 






























Figure 1.1: The basic anatomy of a blood vessel.  Blood vessels are comprised of 
multiple distinct layers, each with its own composition.  The outer most layer is primarily 
constructed from connective tissue and is adjacent to a layer of smooth muscle cells.  The 
smooth muscle cells provide support for the inner most layer of endothelial cells, which 
are anchored to a basement membrane. It is the endothelial cells that carry out functions 















Figure 1.2: Comparison of normal vascular architecture to that of cavernous 
malformation architecture.  Typical vascular structure is one of successive branching with 
larger vessels splitting into smaller vessels until the capillary bed.  These vessels have a 
patent lumen allowing for adequate blood flow. In the case of cavernous malformations, 
the branching structure is replaced by chaotic entanglements.  The entanglements are 
comprised of bulbous vascular sacs that are thin-walled, causing blood to pool and leak, 
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CHAPTER 2 
 
LACK OF CCM1 RESULTS IN HYPERSPROUTING 
AND IMPAIRS RESPONSE 
TO FLOW 
  
 The following chapter was reprinted with permission from the Oxford University 
Press. In addition to myself, the other authors were Aubrey Chan, Mike Redd, 
Christopher Gibson, Chadwick Davis, Dallas Shi, Tiehau Chen, Kandis Carter, Jing Ling, 
Raquel Blanco, Holger Gerhardt, Kevin Whitehead, and Dean Li.  It was originally 
published in Human Molecular Genetics, Epub 2014 Jul 18. I participated in the design, 
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Cerebral cavernous malformation (CCM) is a disease of vascular malformations known to be caused by muta-
tions in one of three genes: CCM1, CCM2 or CCM3. Despite several studies, the mechanism of CCM lesion
onset remainsunclear. UsingaCcm1 knockoutmousemodel,westudied themorphogenesis of early lesion for-
mation in the retina in order to provide insight into potentialmechanisms.We demonstrate that lesions develop
in a stereotypic location andpattern, precededby endothelial hypersprouting as confirmed in a zebrafishmodel
of disease. The vascular defects seen with loss of Ccm1 suggest a defect in endothelial flow response. Taken
together, these results suggest newmechanisms of early CCM disease pathogenesis and provide a framework
for further study.
INTRODUCTION
Cerebral cavernous malformation (CCM) is a disease character-
ized by the formation of dilated vascular lesions in the brain,
retina and skin (1). CCM lesions lack the typical blood-tight
barrier of healthy vessels, resulting in chronic leakiness and
associated inflammation in the surrounding tissue andmost com-
monly lead to headaches, seizures and strokes (2). The disease
affects as much as 0.5% of the population (1,3,4) and can
occur sporadically or be inherited in an autosomal dominant
pattern. The inherited form of the disease is caused by the loss
of function of one of three genes: CCM1, CCM2 or CCM3 (5).
Loss of CCM1, encoding the proteinKrev-interaction trapped
protein-1 (KRIT1), has been shown to disrupt several cellular
processes in vitro and in vivo, including the appropriate organ-
ization of the junctional protein VE-Cadherin and endothelial
cell polarity (6,7). Maintaining physiologic cell–cell junctions
and cell polarity are critical to normal cell migration, flow
response and appropriate signaling by various cascades (8).
There are many other dysfunctional processes associated with
loss of CCM1 in vitro, but how these interact in vivo to disrupt
normal cellular physiology is unknown. Current models and
systems have focused on established lesions, but the preceding
events that initiate lesion formation have not been identified.
While models are useful for interrogation of the disease, later
stage models can mislead when secondary downstream effects
are interpreted as primary defects. Understanding the events
that lead to interpretable signs of disease provides invaluable
insight into the pathophysiology of CCM disease. Therefore
we sought to analyze the developmental events that give rise to
cerebral cavernous malformations associated with loss of
CCM1 in hopes of identifying a morphological tipping point.
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The murine embryonic phenotype associated with homozygous
deletion of Ccm1 consists of severe defects of the aorta and
branchial arch arteries resulting in death, making the murine
embryo a challenging system for studying the onset of CCM
lesion formation (9). We therefore created an inducible mouse
model of CCM disease where loss of a second CCM allele
from the endothelium can be induced after birth in a heterozy-
gous mouse (10,11), allowing normal developmental angiogen-
esis and vascular patterning to occur and mimicking the loss of
heterozygosity thought to predispose to lesion formation. In
our model, we find that retinal lesions develop early in life,
adhere to a strict stereotypical pattern and form following hyper-
sproutingof the retinal vasculature front. In addition,wefind that
cells deficient in CCM1 fail to align to flow in an in vitromodel
and that loss of ccm1 in the zebrafish phenocopies loss of blood
flow, suggesting that failed endothelial flow response may be a
contributing mechanism for CCM1 lesion development.
RESULTS
Generation of CCM1 mutant alleles
A homozygous germline knockout of Ccm1 results in vascular
tissue defects as early as E8.5, including failure of the branchial
arch artery and caudal portion of the dorsal aorta to form a
lumen. These defects restrict and disrupt normal blood flow (9).
In order to determine whether Ccm1 is required autonomously
in endothelial cells, we created a conditional allele in which
exons 4–8 ofCcm1were flanked by loxP sites andCre recombin-
ase was expressed in specific cell types using different
tissue-specific Cre drivers (Supplementary Material, Fig. S1). In
embryos with a germline mutant Ccm1 allele and a second
floxed allele of Ccm1, the endothelial loss of Ccm1 driven by
co-expression of a tissue-specific Cre (Tie2-Cre) (12) resulted in
mice with a homozygous deletion ofCcm1 restricted to the endo-
thelium.With the lossofCcm1 in the endothelium,embryos fail to
survive beyond E12.5 due to failed vascular development. The
branchial arch arteries fail to lumenize properly as seen by
immunofluorescent staining of the vasculature (Fig. 1A–F). We
examined the effects this impaired lumen formation could have
on circulation by performing India inkmicroangiography, a tech-
nique used to assess vessel patency. The disrupted vessel forma-
tion prevented normal passage of ink through the branchial arch
arteries (Fig. 1G andH). This failure in proper embryonic circula-
tion could also be detected by in utero ultrasound (Fig. 1I and J).
The development of the impaired lumen organization and failed
circulation in the endothelial knockout is similar to that described
previously in thegermlineknockout, apatternakin to lossofCcm2
but not Ccm3 (10,11).
Having observed that endothelial specific loss ofCcm1 gener-
ates defects that are nearly indistinguishable from the embryonic
defects in germline knockouts (9), we inquired if post-natal in-
duction of loss of a second allele of Ccm1 would produce a
murine model that would more closely mimic human disease.
Therefore, we utilized an inducible Cre, PDGFb-iCreERT2,
the expression of which is also restricted primarily to the endo-
thelium, but is activated only upon exposure to tamoxifen (13).
To confirm the endothelial specificity, we crossed the PDGFb-
CreERT2 mouse with the mTmG reporter mouse. Following
tamoxifen administration the GFP expression was detected in
the endothelium as confirmed with a co-stain with the endothe-
lial marker lectin (Supplementary Material, Fig. S2). This
system allowed us to knockout the second Ccm1 allele at any
Figure1.Endothelial lossofCCM1results inabnormal embryonicvasculardevel-
opment. (A andB) Visualization of the vasculature, as indicated by lectin stain, or
whole-mount embryos at E9.5. (C and E) Close-up image of the branchial arch
artery morphology from the indicated white outlines in A and B. (D and F) Illus-
tration of the branchial arch artery from the adjacent panel, included to highlight
visualization. (G and H) Brightfield images of ink injected E9.5 embryos. Light
blue arrows indicate areas where ink was able to flow through the vasculature.
(I and J) In utero ultrasound of blood flow on E9.5 embryos. Embryos are
located in thecenterofeach imagewith thebox indicating the areabeingmonitored
for flow. The heatmap bar on the left indicates the directionality of the blood flow,
red indicates blood flow towards the camera, blue indicates blood flow away from
the camera. Absence of color demonstrates absence of flow.
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time point after birth, bypassing the lethal embryonic defects.
Endothelial specific deletion of the floxed allele can be obtained
by crossing the PDGF-iCreERT2 allele into the floxed Ccm1
background. This allele results in an induced endothelial knock-
out (ieKO) upon stimulation with tamoxifen. The loss of endo-
thelial Ccm1 following tamoxifen treatment at birth leads to
the formation of cavernous malformations in the brains of all
animals.We tracked thedevelopment fromsimple, dilated telan-
giectasias to largemulti-chambered caverns over time using live
animal magnetic resonance imaging (MRI). Lesion pathology
includes vascular leak, which results in the deposition of hemo-
siderinwhich is detected by theMRI and presents as darkmasses
within the brain. These lesions arise throughout the entire brain
by 2months and progress in severity with time (Fig. 2A–F). The
presence of these lesions decreased the survival rate in mice,
which correlated with increased lesion content (Fig. 2G and H).
Further analysis showed that histologically these lesions pheno-
copy the hallmarks of human disease with dilated, thin-walled
Figure 2.Post-natal endothelial loss of CCM1phenocopies human disease. (A–F) Live animalmagnetic resonance imaging (MRI) images ofmice. Each row is from
onemouse,kept alive, and imagedsuccessivelyover timeat the ages indicated in thepanel.Light bluearrows indicateCCMlesions. (G)Kaplan–Meier survival curve,
animals were given tamoxifen at birth and followed through life. Animals that survived were euthanized at 8 months of age. (H) Quantification of CCM brain lesion
content over time. Lesion burden is determined as the total number of lesions observed in each tomographic view (slice) of the MRI per mouse. (I–N) Histological
staining comparing samples fromhumanCCM1 lesions and lesions fromCCM1knockoutmice.H&Estaining indicates tissuemorphology of the lesion. Iron staining
indicates leak into the brain tissue surrounding the lesion. Trichrome staining indicates fibrosis surrounding the lesion. Scale bar at 200 mm. (O) Whole-brain H&E
histology of an 8-month old CCM1 knockout mouse. Black arrows indicate CCM lesions.
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caverns surrounded by hemosiderin deposits (reflecting ongoing
vascular leak), inflammation and fibrosis (Fig. 2I–O) (14).
Lesions also consistently form in the retinas of all affected
animals (Fig. 3). Because of its size and ease of access, the
retina is well characterized with respect to normal vascular devel-
opment (15) and is thus an ideal focal point for describing the early
Figure 3.Retinal CCMs develop in a stereotypical location. (A andB) Schematic indicatingmouse retinal orientation, right inA and left in B,with an example angio-
graph showing the expected retinal vascular morphology. Adjacent to the example angiography are live angiographs taken from either control or CCM1 knockout
mouse in the appropriate orientation. Blue arrows indicate lesion location. Scale bars are at 1000 mm. (C and D) Visualization of retinal vascular, as indicated by
lectin staining, in whole-mount retinas from the mice shown in B (left eyes). (E and F) Schematic illustration highlighting lesion location and morphology. The
superior and inferior veins are colored in purple with the major surrounding vessels in light gray.
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developmental mechanism of CCM lesion formation. Moreover,
the retina is amenable to live-animal angiography, permitting us
to ask questions of lesion perfusion as well as location.
Inorder toexamine the locationandperfusionof retinal cavern-
ousmalformations,we studied ieKOmicewith in vivofluorescein
angiography. Using this method, we found that lesions stereotyp-
ically arise in the veins located both most superior and inferior
within the retina (Fig. 3A and B). Extending out from the trunk
of these veins is a tangled network of spherical vascular sacs,
the hallmark of cavernous malformation anatomy (16). The indi-
vidual caverns are confined to the periphery, vary in size and are
interconnected by narrow vessels. These vessels also appear to
be fully perfused as indicated by the ability of the fluorescein to
fill the lesions. Visualization of these retinas via dissection and
lectin staining confirmed our observations from the angiography
(Fig. 3C–F).
We next examined the timing of lesion formation by looking at
a series of retinas frommice at different ages. Retinas from ieKO
remain indistinguishable fromcontrolsuntilpostnatalDay7when
the vascular network begins to exhibit vessel dilation and failure
of plexus coalescence. Over time, the vascular dilations resolve
into caverns and by p21 the lesions assume the well-defined
morphology of a mature retinal CCM and recapitulate human
retinal angiomas (Fig. 4A–J) (16). We found that this pattern of
development held true for 100% of the retinas examined and
that all of the Ccm1 knockouts developed retinal lesions.
The normal growth of retinal vasculature begins at birth with
endothelial cells expanding across the superficial layer (17).
At P8 the formation of a vascular network in the deep retinal
layer begins. Eventually the superficial and deep networks are
joined together by the formation of an intermediate network.
Once these layers are interconnected and the vascular network
has reached the periphery of the retina, angiogenesis is complete
and the retinal vasculature is mature. We found that CCM lesions
arose from the superficial vascular plexus and remained superficial
until later in disease progression. At P10 the dilations observed in
early disease onset were limited to the superficial layer with no
dilated caverns observed in the deep or intermediate layers
(Fig. 4K′ –R′). By 5 months the main body of the lesion remained
superficial but some extension of caverns could be observed in the
deeper layers as the mature lesion expanded in size (Fig. 4K–R).
The superficial location of the lesions could also be seen using
cross sectional analysis (Fig. 4S–X). To further expand on our
observation that lesionswere perfusable, we conducted ultrasound
studies of the retinal vasculature. We found no difference in blood
flowbetween ieKO and controlmice, implying that retinal cavern-
ous malformations are low flow lesions that do not increase the
overall retinal blood flow (Fig. 5A–C).
The first 2 weeks of retinal development relies heavily on
active angiogenesis, particularly as the superficial plexus
expands (18,19). However, by P21, retinal angiogenesis is com-
plete and the vascular structure is mature. To determine if lesion
formationwas dependent upon this early angiogenic process, we
inactivatedCcm1 at varying time points after birth and followed
the subsequent retinal development. We found that when Ccm1
is lost at the critical point of phenotype distinction, P7, lesions do
form in the periphery of the retina by P21 and that these lesions
demonstrate similar morphology as those of mice induced at
birth, though the severity and size of the lesions are diminished
(Fig. 5D and E). If we delay delivery of tamoxifen such that
Ccm1 is not deleted until P21, after the retinal vasculature is
mature, we find that lesions do not form (Fig. 5F). Therefore,
our results in a distinct animal model confirm those of others
that active angiogenesis is required for lesion formation (20).
Lack of CCM1 induces hypersprouting
Sproutingangiogenesis requires thecoordinated effortofmultiple
endothelial cells and is foundat the leadingedgeof the developing
vascular plexus (18). It is dictated by the stochastic response of
select endothelial cells responding to angiogenic stimuli. The
responsive cells that form the sprouts (called tip cells) extend,
migrate and fuse to develop a vascular plexus (19). The non-
responsive cells that remain non-migratory are known as stalk
cells.Therefore, it ispossible that excessive sproutingand the sub-
sequent anastomosis could contribute to lesion onset. Prior to
vessel dilation, we find that retinas from ieKO mice induced
at P1, exhibit endothelial hypersprouting (Fig. 6A–C). The
sprouts observed showed a tip cell phenotype as indicated by
the tipcellmarkerPDGFbaswellascellularmorphology(Supple-
mentary Material, Fig. S2). Although the retina allows better
observation of the three-dimensional architecture of the cavern-
ous malformation than the mouse brain, it is difficult to observe
the dynamics of vascular development in the intact mouse eye
in real time. Sprouting angiogenesis is a dynamic process, there-
fore we sought to explore this phenotype in a model more amen-
able to live imaging. Zebrafish have the advantage of ex vivo
development and transparency that allow the real-time observa-
tion of sprouting angiogenesis. (21). Therefore, we sought to
evaluate sprouting angiogenesis in a zebrafish model.
To examine early angiogenic sprouting, we injected a mor-
pholino targeted against ccm1 (22) (or a scrambled control) at
the single cell stage of embryos carrying the endothelial specific
reporter kdrl;GFP. We found that the caudal vein plexus (CVP)
development exhibited hypersprouting at 28 h post-fertilization
(hpf) (Fig. 6DandE) and thenwent on todevelop into a largevas-
cular cavern, a defect similar to early retinal lesions (Fig. 6F–K).
The dilation of the CVP is also reminiscent of the dilated caudal
dorsal aorta in developing CCM1 knockout mouse embryos,
which also demonstrated alterations in artery/vein specification.
Loss of this morphological distinction between the caudal artery
and the cadual vein in the zebrafish and the resulting dilated
morphology, highlights overlap in the vascular pathology of
bothmouse and zebrafish.Under normal developmental circum-
stances the CVP arises from the process of ventral sprouting.
Ventral sprouting initiates at 20 hpf when endothelial cells
begins to sprout and migrate from the dorsal aorta (23). The
cells then expand as a population and coalesce into the distinct
vascular network of the CVP (Supplementary Material, Movie
S1). In contrast, when ccm1 is reduced, the cells do not form a
distinct vascular network and theCVPdevelops as a large vascu-
lar sac (Supplementary Material, Movie S2). Therefore these
data suggest that the formation of CCMs could arise from a
defect of population-wide endothelial hypersprouting and anas-
tomosis, resulting in a malformed vascular cavern.
Lack of CCM1 impairs flow response
Flow can regulate vascular morphology during development
(24) and shear stress can direct overall network architecture.
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Furthermorebloodflowcanattenuate endothelial sprouting (25).
The effects of flow and the endothelial mechanism to detect flow
may provide an explanation for the hypersprouting observed as
well as why lesions form stereotypically.
The silent heart morpholino, which knocks down cardiac
troponin, results in a non-beating heart resulting in a complete
lack of blood flow (26). We find that at 28 hpf silent heart mor-
phants exhibit the same hypersprouting defect as seen in the
Figure 4. Retinal CCMs develop early and are limited to the superficial vascular plexus. (A–J) Timecourse of retinal vascular development in denoted genotypes.
Retinas were dissected at the ages indicated, then lectin stained and imaged. Each image depicts a single leaflet of the dissected retina. Light blue arrows indicate the
location of lesion development. Scale bars ¼ 200 um. (K–R) Retinal depth images taken at 5 months of age from either a control or CCM1 knockout mouse. Each
imagewas taken using confocal microscopywith themicroscope focused in the retinal plane indicated in the panel (N,R represent merged image. Blue ¼ deep layer.
Red ¼ intermediate layer. Green ¼ superficial layer). K′ –R′) Retinal depth images taken at 10 days of age from either a control or CCM1 knockout mouse. Each
image was taken using confocal microscopy with the microscope focused in the retinal plane indicated in the panel (N,R represent merged image. Blue ¼ deep
layer. Red ¼ intermediate layer. Green ¼ superficial layer). (S–X) Cross sectional images from 5-month-old retinas from either control or CCM1 knockout mice.
Each retina was frozen in OCT, sectioned and stained with lectin and DAPI to visualize both the vasculature and the surrounding tissue. (Y) Diagram depicting
lesion growth across the retina. All scale bars set at 200 mm.
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ccm1 morphants. In addition, the silent heart morphants go on
to develop the CVP dilation as seen in the ccm1 morphants
(Fig. 7A–G, Supplementary Material, Movie S3). However,
flow is present in 37% of the ccm1 morphants and yet these
morphants still develop the samedefects (SupplementaryMater-
ial, Movies S4 and S5), suggesting defects in blood flow or
Figure 5.Retinal CCMs do not exhibit disrupted hemodynamics and are limited to a specific developmental window. (A and B) Ultrasound images of whole retinal
vasculature fromeither control or knockoutmice, orientation is en facewith the optic nerve in the center of the eye.Red color indicates bloodflow towards the camera,
blue color indicates blood flow away from the camera. (C) Quantification of the volume time interval (VTI) of both left and right eyes as calculated by the Vevo2100
software. (D–F)Visualization of the retinal vasculature, as indicated by lectin stain, fromaCCM1knockoutmouse thatwas induced at P1 (D imaged at P21), induced
at P7 (E imaged at P21) or induced P21 (F imaged at 8 months). (G andH) Close-up of the vascular lesion from the insets in E and F. Scale bars set at 1000 mm.
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the ability to sense blood flow might be contributing to lesion
formation.
We therefore hypothesized that CCM1 is required for the
endothelial cell to sense or respond to flow. We predicted that
cells deficient in CCM1 would exhibit hallmark defects, such
as an inability to align to the direction of flow (27). To test endo-
thelial response to shear stress, we suppressedCCM1 expression
inmonolayers of HUVEC cells using siRNA. Thesemonolayers
were then exposed to a period of laminar shear stress and their
alignment was analyzed by measuring the major angle of an
ellipse fitted to each cell in relation to the direction of flow.
Cells depleted of CCM1 failed to align with the direction of
blood flow, consistent with a role for flow in the formation of
CCM lesions (Fig. 7H–L).
Figure6.LossofCCMresults in hypersprouting. (A andB) Images showing sproutingat the retinal vascular front atDayp7as indicatedby lectin stain.White asterisks
denote sprouts. Scale bars set at 50 mm. (C) Quantification of sprouts per field at p7, P-value,0.05. (D andE) Endothelial sprouting of the zebrafish CVP at 28hpf.
White asterisks denote sprouts. Scale bars set at 100 mm. (F and G) Zebrafish tail vasculature at 48 hpf. White box indicates area of inset. (H and I) Inset of tail
vasculature. (J andK) Schematic illustration highlighting the tail morphology seen in F and G.
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The current field of CCM study has focused primarily on late-
stage disease, with read-outs being in mature disease states.
Suchanapproach is limited inscopeandcanoverlook the stimulus
that initiates lesion formation. Understanding the developmental
process of CCM formation is critical in identifying the key
molecular events that lead to disease onset. By taking a develop-
mental approach, our study represents a careful analysis of the
early morphological events of CCM formation. We demonstrate
that retinal lesions develop in a stereotypic pattern and location.
In addition, we find thatCcm1must be lost during a particular de-
velopmental window in order for lesions to form, consistent with
the observations of Boulday et al. (20). Furthermore, we find that
prior to any sort of vascular dilation phenotype endothelial cells
exhibit a hypersproutingbehavior.Hypersprouting inconjunction
with the predictable development of the lesions from veins sug-
gests that local cuesmay be a contributing factor to disease onset.
Previous work demonstrating that blood flow can regulate
sprouting and organization suggested a potential mechanism
Figure 7.Loss of CCM results in impaired flow response. (A–C) Images of zebrafish tail morphology at 48 hpf.White box indicates area of inset. (D–F) Inset of tail
vasculature. (G) Quantification of endothelial CVP sprouting at 28 hpf. P-value,0.05. (H) Quantification of I-L, P-value,0.0001. (I–L) Endothelial monolayers
stained with phalloidin and exposed to either static (F andG) or flow (H and I) conditions. Scale bars at 40 mm.
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for the development of CCM lesions. The difference in arterial
and venous flow rates provides local developmental cues to
endothelial cells via the process of flow response (24).
A defect in flow response could explain why lesions develop in
a stereotypic pattern and are restricted to the superior and inferior
veins. Our observation that endothelial cells deficient in CCM1
do not align to flow and the ability of silent heart to phenocopy
the sprouting anddilation phenotype seenwith ccm1knockdown
support the hypothesis that response to flowmay be disrupted. In
addition, in a previous work by Hogan et al. (28) it was
observed in vivo that loss of CCM1 results in a round cell
shape that does not elongate in the direction of flow. This
observation is consistent with our finding of failed alignment
in vitro. If endothelial cells cannot sense or respond to the
local flow appropriately, development of the local vascular
architecture could be disrupted. Further study is needed in
order to determine whether the defect is in sensing flow or in
response to flow and how those processes may influence the
development of the local vasculature. Taken together, our
data demonstrate the predictable nature of retinal CCMs and
provide a new approach to the study of this disease. Further-
more, our results illustrate the importance of both the physi-
ology and environment in the etiology of vascular disease.
MATERIALS AND METHODS
Mice
Animals were housed at the University of Utah and all experi-
ments were approved by the University of Utah Institutional
Animal Care and Use Committee. The Ccm1 floxed allele was
generated by inserting LoxP sites that flank exons 4–8
(Krit1tm1Kwhi, here referred to as Ccm1flox). A germline mutant
allele (Krit1tm1.1Kwhi, here referred to as Ccm1-) was generated
by crossing thesemice againstmice expressingCre recombinase
in the germline. See Supplementary Material, Figure S1. The
mT/mG (B6.129 (Cg)-Gt (ROSA)26Sortm4(ACTB-tdTomato,-
EGFP)Luo/J) was obtained from Jackson Labs.
Human samples
Human tissue samples were provided by Connie Lee and Amy
Akers (Angioma Alliance, Norfolk, VA, USA) and Randy
Jensen (University of Utah, Salt Lake City, UT, USA) and
were obtained with written informed consent. Human experi-
ments were approved by the Institutional Review Board of the
University of Utah.
Zebrafish
Zebrafishweremaintained under standard husbandry conditions
in the University of Utah CZAR and were approved by IACUC.
The transgenic lines used were Tg (kdrl:GFP) for endothelial
visualization and Tg (gata1:dsRed) for red blood cell visualiza-
tion. Morpholino injections were done using standard injection
techniques and the previously described morpholinos for
CCM1 (22) and Silent Heart (26).
Analysis of mouse embyos
Embryos were harvested at time indicated and confocal im-
munofluorescence or fetal ultrasound was performed as previ-
ously described (11). Ink injections were done as previously
described (29)
MRI
MRI studies were conducted as previously described (10)
Antibodies
For endothelial visualization in retina immunofluorescence
Alexa Fluor Isolectin GS-IB4 (Invitrogen) was used. For actin
visualization Alexa Fluor phalloidin (Invitrogen) was used.
Histology
Adult mouse brains were removed after fixation in 4% formal-
dehyde for at least 3 days or zinc-buffered formalin overnight.
The brain was then removed and sliced into three coronal sec-
tions and was embedded into paraffin by standard protocol.
Histological staining for iron and trichrome were carried out
using the Dako Artisan system according to manufacturer’s
instructions.
Microscopy
All fluorescent still images were taken using the Nikon AR1 con-
focal microscope using either a ×10, ×20 or ×40 objective. For
live zebrafish imaging, the Nikon Eclipse Ti widefield was used
in conjunction with temperature controlled stage. Fish were
mounted in 1% low-melt agarose on a glass cover slip. The cover-
slips were mounted onto the stage and E3 solution was used to
prevent the agarose from drying. Temperature in the imaging
chamber was set to 308C. For brightfield histological imaging,
the Zeiss Axioplan 2 microscope was used with either the ×10
or ×4 objective. For the whole-brain histology image (Fig. 2O)
several individual panels were taken and then photo-merged
into one single image.
Live animal angiography
Prior to anesthesia, 1% Tropicamide was administered to
animals to facilitate eye dilation. Animals were then anesthe-
tized using isoflurane, injected with 100 ml of fluorescein, and
positioned on the imaging platform. Images were then taken
using the Heidelberg SPECTRALIS Ultra-Widefield Angiog-
raphyModulewith the 1028 lenswhile animalswere held in con-
sistent orientation.
Retinal processing
Eyes were enucleated and fixed overnight in 4% Paraformalde-
hyde (PFA) at 48C. Retinas were then dissected and stained as
previously described (19). After staining, retinas were placed
into phosphate buffered saline (PBS), cut four times to section
the cup into leaflets, and then flat-mounted onto slides using
Dako Faramount Aqueous mounting media. For cross-sectional
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analysis, eyes were embedded into OCT for frozen sectioning
per standard protocol. Sections were cut at 10 mm thickness
and then stained with both lectin and DAPI, then mounted with
Dako Faramount Aqueous mounting media for imaging.
Fluorescence in situ hybridization
Eyes were collected at Day 5 (P5), fixed with 4% PFA 4H and
immediately dissected. Retinas were fixed ON with 4% PFA
at 4C and transferred to METOH the day after and stored at
2808C Retinas were rehydrated by thorough washing steps
with 75, 50 and 25% METOH–PBS–0.1%Tween at RT. Then
retinas were treated with Proteinase K (Invitrogen 20 mg/ml.
Cat. no. 25530-049) during 20 min, fixed with 4%PFA-0.1%
Glutaraldehyde (Sigma, 25% glutaraldehyde solution. Cat. no.
G5882) and pre-hybridize at 658Cduring 2HwithHb4 hybridiza-
tion buffer. Probe-hybridization was performed ON at 658C
using Hb4D5 buffer. Hybridization mix was prepared using the
digoxigenin (DIG)-probe at concentration of 1 mg/ml. The day
after, retinas were thorough washing steps using 50% formamide
deionized (Sigma. Cat. no. F9037)-2XSSCT, 2XSSCT and
0.2XSSCT at 658C, cool down on PBS–0.1%Tween and
blocked with PBS–0.1%Tween–8%Sheep serum (Sigma. Cat.
no. S2263) during 2H at RT. After that, retinas were incubated
ON at 48C with the sheep anti-DIG peroxidase (POD) antibody
(1:500; Anti-DIG-POD Fab fragments. Roche. Cat. no.
11207733910). Next day, retinas were washed during 2H at
intervals of 30 min with TBS–0.1%Tween and incubated during
20–30 min with fluorescein tyramide solution (TSA) diluted
(1:500) on PBS–0.1%Tween, at RT. For TSA solution synthesis
check the link, http://www.xenbase.org/xenwiki/index.php/
Flourescin_Tyramide_Synthesis.
Posteriorly, 0.001%H2O2was added to the TSA solution to ac-
tivate TSA reaction. After 30–45 min TSA reaction was stopped
washing quickly the retinas with PBS several times. Before pro-
ceeding with Isolectin IF, retinas were washed during 2 day at
48C in slow agitation with PBS–0.1%Tween to reduce ISH
unspecific signal and post-fixed with 4%PFA.
Ultrasound studies of the Eye
Mice were anesthetized with 1.5% isoflurane inhalational anes-
thetic and monitored for pulse and respiration. Images were
acquired from the eye, including specific studies of the retinal
artery and vein with B-mode, color and pulsed-wave Doppler
modes using a Vevo 2100 high frequency ultrasound machine
(VisualSonics).
Cell culture and flow
Human umbilical vein endothelial cells were obtained from
Lonza and grown according to the manufacturer’s instructions.
HumanCCM1or non-targeting siRNAwas obtained fromDhar-
macon. EC transfection with siRNAs was carried out in growth
media with 1% serum with details of the siRNA transfection
protocol as previously described (30). For flow experiments,
cells were plated in IBIDI 8-well chamber slides (VI0.4) and
exposed to a 16 dynes/cm2 flow rate (simulating arterial shear
stress) or static conditions for 24 h. Cells were then fixed with
4%PFA and actin cytoskeletonwas visualized using phalloidin.
Statistical analysis
For CCM penetrance and lesion content, we performed a two-
tailed t-test. For quantification of sprouting, we performed a
2-tailed t-test. For analysis of cell alignment, we performed a
two-way analysis of variance test. P-values are as indicated in
the figure legends.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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 Cerebral cavernous malformations (CCM) are common vascular lesions are of the 
central nervous system that occur in both sporadic and familial forms. Evidence is 
gathering that the loss of both alleles for any of three disease-associated genes underlies 
both familial and sporadic disease through a so-called “two hit model” analogous to 
Knudson’s classic description for retinoblastoma. Using an animal model of the most 
severe and susceptible form of familial disease, Ccm3, we show that delaying the timing 
of the second genetic hit by 3 weeks completely eliminates disease susceptibility. Our 
data suggest genetic factors are sufficient to cause CCM lesions only if they occur early 
in life, calling the universal applicability of the two genetic hit model into question. 
Using viral vectors to deliver a genetic insult, a local cytokine insult, or both to adult 
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mice, we show that lesions in adult mice form only in the presence of both genetic and 
environmental triggers.  These data allow the prevailing genetic model for CCM disease 
to explain the lifelong propensity to form new lesions by demonstrating the synergistic 
importance of the environmental context. 
 
3.3 Introduction 
 Cerebral cavernous malformations (CCM) are relatively common vascular 
malformations of the central nervous system with considerable morbidity. These dilated, 
thin-walled vessels are prone to vascular leak and rupture and are a significant cause of 
hemorrhagic stroke (33, 34). They are found with a prevalence of 1 in 200 persons (35-
37), and occur in both sporadic and familial forms. For both forms of the disease, the 
factors associated with lesion formation are incompletely understood. Familial forms 
have allowed the identification of three genes that are associated with CCM, including 
CCM1 encoding KRIT1 (38-40), CCM2 encoding OSM/Malcavernin (41-43), and 
CCM3 encoding PDCD10 (44). Loss of function alleles in any of these three genes 
afflicts heterozygous carriers with CCM and leads to a more severe form of CCM than 
sporadic disease characterized by a tendency to form multiple lesions and higher 
likelihood of symptoms. The earlier onset of symptoms and multiple lesions in 
heterozygous individuals have suggested the possibility of a “two-hit” genetic mechanism 
originally suggested by Knudson to explain the development of retinoblastoma (45). Case 
reports have identified biallelic mutations, one somatic and one germline, for each of the 
three CCM genes in surgically excised lesions (46-49). Our laboratory and others have 
shown that the perinatal inactivation of both copies of the CCM genes in the endothelium 
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of mice is sufficient to induce cavernous malformations in the central nervous system 
(29, 50). Two genetic “hits” in the first week of life were shown to be sufficient to induce 
disease in mice.  
 The compelling evidence supporting the genetic basis of disease has nearly 
silenced earlier lines of inquiry into environmental causes for CCM. Yet observational 
data provide reason to believe that environmental factors also influence the formation and 
progression of CCM disease. Case reports have demonstrated an association between 
progressive lesion development and elevated serum levels of cytokines, including 
vascular endothelial growth factor (51, 52). The brain is predisposed to respond with 
increased cytokine levels to local injury or inflammation (53-55).  Cavernous 
malformations are associated with inflammatory cells and immune activation, although a 
cause-effect relationship has not been shown (56, 57). In other patients, lesions have been 
observed to form in brain regions following radiation injury (58). It is possible that the 
environmental changes induced by radiation injury are key contributors, although genetic 
damage is also likely to be present. In sporadic disease, prominent local venous structures 
have been observed that suggest an abnormal microcirculatory environment (59, 60). 
These observations argue for the importance of environmental “hits” in the promotion of 
lesion development.  
 The requirement for two genetic hits in each individual CCM lesion has not been 
shown. In familial CCM it is not uncommon for patients to have dozens or even hundreds 
of individual lesions. It has not been possible to test whether the burden of disease in a 
given patient is the consequence of greater genomic instability and more independent 
genetic insults, or whether local environmental cues (such as trauma, inflammation or 
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cytokine expression) play a critical contributing factor. One of us has been a key 
proponent of exploring the local influence of cytokines on modulating genetic disease 
(61-63). We sought to explore the interaction of genetic lesions with local environmental 
cues in the formation of CCM lesions in our mouse model of CCM.  
Mice heterozygous for null mutations in Ccm3 will develop lesions at a frequency of 
100% if given a second hit in their endothelial cells at birth (50). This model system 
shows widespread, early-induced somatic inactivation of Ccm3 in almost all endothelial 
cells of the brain, retina, and most other organs. The extent of the genetic hit exceeded 
that expected to occur naturally in man, yet lesions were detected in only a small minority 
of vessels, predominantly within the brain. The fact that one cluster of brain endothelial 
cells was induced to form a CCM lesion, while adjacent endothelial cells with the 
identical genetic lesion retained normal histology, was suggestive evidence to us that 
additional local environmental factors influence CCM formation. 
Here we show that the induced inactivation of Ccm3 is only sufficient to induce CCM 
disease if delivered within a narrow susceptible window of time in early development. 
The induction of loss of heterozygosity within the endothelium at the time of weaning 
does not lead to lesion formation in either the brain or the retina. We therefore tested 
whether local cytokine expression could synergize with this genetic insult to induce 
CCM. We will show in this manuscript that delivery of vascular endothelial growth factor 
given along with the induced inactivation of Ccm3 in adulthood is sufficient to lead to 
CCM lesion formation. These data indicate that environmental factors, such as cytokines 
and inflammation, play an important role in the pathogenesis of this disease and suggest 
that targeting the brain microenvironment that facilitates CCM formation may be a 
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valuable strategy in ameliorating the disease. 
 
3.4 Results and Discussion 
 Cerebral cavernous malformations affect two distinct populations of people. One 
group develops solitary lesions and lacks a family history of disease. These lesions are 
termed sporadic CCMs. Another group develops pathologically identical lesions in 
multiple, discrete locations of the central nervous system and have inheritable, familial 
disease. The prevailing theory to explain the basis of sporadic disease is the gradual 
acquisition of separate genetic insults to both copies of a CCM gene in the endothelial 
cells of the affected individual. This “two-hit” theory of CCM development could 
account for the greater likelihood of lesions in those with one inherited mutant allele and 
would reconcile the mechanism for lesion formation in both groups of patients into one 
common pathology. Support for this prevailing theory is found in both human and mouse 
experimentation. Surgically excised human samples from familial CCM patients have 
been analyzed for evidence of second genetic hits, and examples of biallelic somatic and 
germline mutations have been found for each of the three known CCM genes (47-49). In 
mice, a number of different laboratories have pursued strategies to create second genetic 
hits with targeted mutations of CCM genes. Using several different tamoxifen inducible 
Cre-recombinase systems to deliver controlled, widespread somatic endothelial “second 
hit” mutations at birth, our laboratory (50) and other laboratories (29) have confirmed 
that this mechanism is active in mice. An alternative strategy has also been pursued in 
which the “second hit” is the result of genomic instability in strains with high rates of 
spontaneous mutations (64). These naturally occurring mutations are more likely to 
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mimic those seen in patients. In this model the timing and nature of the second genetic hit 
is not controlled and is difficult to confirm, and yet the same pathology results. 
 Earlier work had suggested a developmental susceptibility to cavernous 
malformations and that the timing of the second hit might be important (29). We chose to 
focus our experiments on mice with mutations in Ccm3, the most severe and early onset 
model of CCM. The induced loss of endothelial Ccm3 at birth (P1) leads to CCM lesion 
formation in the brains and retinas of all mice and can be detected by MRI in the brain by 
2 months of age (50). To judge the effectiveness of late induction of endothelial Ccm3 
mutation, we again prepared inducible endothelial knockout mice. These mice have one 
germline null allele for Ccm3 with another floxed allele with exons 3 through 8 of Ccm3 
flanked by loxP sites, targeted for Cre-mediated recombination. These mice were also 
bred to express a tamoxifen inducible Cre recombinase in endothelial cells  (Ccm3flox/-
;Pdgfb-iCreERT2) (65). Using this system, the administration of tamoxifen results in 
endothelial-specific loss of Ccm3.  We compared mice with induction at P1 with mice 
induced later in development at weaning on P21. Inducible reporter gene activity 
demonstrated that tamoxifen treatment resulted in widespread endothelial Cre activity in 
the brain and retina when given at day 21 as judged by induced green fluorescence seen 
only in mice treated with tamoxifen (Figure 3.1A). Cavernous malformations were only 
seen if the genetic lesion was delivered early after birth and were not seen if induction 
was performed at weaning. Our previous work had shown 100% penetrance at first 
assessment by MRI at 2 months of age, with heavy lesion burden and some death 
beginning at 3 months of age (50). All mice treated at P1 were found to have CCM 
lesions by histology in both the brain and retina. In distinct contrast, no mice treated with 
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tamoxifen at P21 developed CCM lesions of either brain or retina by 7 months of age 
(Figure 3.1B and C), demonstrating that while loss of heterozygosity is sufficient for 
disease in neonatal mice, an additional lesion promoting factor or factors is necessary by 
P21. Delaying the second hit by a mere 3 weeks resulted in a dramatic change in the 
phenotype with distinctly unusual absence of lesions and mortality by 7 months in our 
most vulnerable genotype. Thus, the animal model data allows only a limited allowance 
of the two genetic hit model as the sole explanation for lesion formation, restricted to a 
brief, developmentally vulnerable window of time. Although the equivalent vulnerable 
period in humans is not clarified, it strains the imagination to think that all of the genetic 
hits and lesion initiation must occur early in life. Longitudinal studies in man have shown 
the progressive development of new lesions throughout life into adulthood (33). Our 
targeted genetic animal models do not provide a suitable explanation for these late-
occurring lesions, which is troubling for the two genetic hit theory as the sole explanation 
for the gradually appearing and progressive lesions seen in familial CCM. 
Clinical observations first suggested an alternative explanation to the genetic basis 
for new lesion development. Occasional patients have been described with an unusually 
rapid appearance of multiple new lesions over a short period of time. This phenomenon 
was observed to correlate with high serum levels of vascular endothelial growth factor 
(51, 52), suggesting that nongenetic, environmental triggers may act as an alternative 
explanation for lesion development. 
To more directly test the environmental hypothesis, we designed an experiment in 
which the effects of both gene inactivation and angiogenesis could be assessed 
independently and in combination. Using viral vectors to drive expression of both Cre 
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recombinase and vascular endothelial growth factor (VEGF), localized central nervous 
system angiogenesis and/or homozygous Ccm3 mutation were induced by stereotactic 
injection of appropriate vectors. Four separate groups of mice were prepared (Table 1). 
All mice were homozygous for the floxed Ccm3 allele (Ccm3flox/flox) and vulnerable to 
complete loss of Ccm3 with the expression of Cre recombinase. Each group of mice 
received two viral vectors, an adenovirus expressing either Cre recombinase or GFP 
(Adeno-Cre or Adeno-GFP), and an adeno-associated virus expressing either VEGF or 
beta-galactosidase (AAV-VEGF or AAV-LacZ). Thus one group received two control 
viruses with neither VEGF nor Cre, one group received both VEGF and Cre, and one 
group each received either VEGF or Cre in combination with a control virus. Injections 
were performed on adult mice between 6 and 8 weeks of age, and after a further 6 weeks 
mice were studied for vascular defects.  
Using this controlled model we were able to produce CCM lesions in adult mice, 
but only in those receiving both the genetic insult and cytokine induction. We noticed the 
presence of stage 1 cavernous malformations (64) in the brains of mice treated with both 
Cre and VEGF (Figure 3.2A). We did not note stage 1 lesions in any other group. Neither 
Cre recombinase nor VEGF alone were sufficient to induce cavernous malformations. A 
more detailed analysis was performed by staining sections with a fluorescent endothelial 
specific lectin and measuring the diameter of all vessels within the microscope field 
(Figure 3.2B). Mice receiving both VEGF and Cre had a population of vessels greater 
than 80 micrometers in diameter (including both stage 1 lesions and preclinical vessel 
enlargement) that was not present in any other group (Figure 3.2C). 
The effects of both VEGF and Cre recombinase were detected in mice that 
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received appropriate viral treatments. Treatment with AAV-VEGF resulted in 
angiogenesis and localized edema that was readily detected as a low intensity signal by 
MRI (Figure 3.3). There was no difference in the extent of edema whether Cre 
recombinase was present or not.  The presence of edema obscured the ability to detect 
vascular lesions in mice treated with VEGF by MRI.  
To confirm equal efficacy of gene inactivation, we used laser capture 
microdissection to remove tissue from slides focusing on the treated side of the brain. To 
ensure that equal regions were compared, we sampled several adjacent circular regions of 
brain from all sections (Figure 3.3). After purifying genomic DNA, a genomic copy 
number assay was performed using quantitative PCR. The region with the lowest 
detected copy number was assumed to include the area of peak viral expression and gene 
inactivation. To control for assay efficiency, we compared untreated control mice that 
were homozygous floxed (Ccm3flox/flox) with mice that were heterozygous for the null 
allele resulting from germline Cre inactivation (Ccm3flox/-).  In the experimental samples, 
Cre was found to effectively reduce the Ccm3 copy number in bulk tissue obtained from 
the injected area. Cotreatment with VEGF did not enhance or inhibit gene inactivation, as 
mice receiving Cre recombinase with LacZ  control vector had equal loss of Ccm3 as 
those receiving Cre and VEGF (Figure 3.4).  
This work therefore reconciles the differing theories of CCM lesion development. 
We demonstrate that cytokines and genetic factors are synergistic in the development of 
CCM lesions. Neither a susceptible environmental insult such as localized VEGF 
expression, nor the induction of genetic hits in adult mice is alone sufficient to reproduce 
CCM pathology, but the two insults together lead to disease. Our work suggests a model 
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in which the genetic hits are required to give disease susceptibility, but lesion initiation 
occurs when the endothelium is environmentally vulnerable. In mice this vulnerability 
occurs naturally in early development (Figure 3.5A), and the genetic insult alone can 
trigger lesion development. Outside of the vulnerable developmental window the genetic 
lesion no longer is sufficient to induce formation of a cavernous malformation (Figure 
3.5B). The late, progressive lesion development that has been seen in clinical CCM can 
be explained by an initial genetic predisposition with lesion initiation triggered by local 
environmental factors that activate the endothelium (Figure 3.5C). This model can also 
explain the observation that lesions in mice with widespread endothelial CCM gene 
inactivation at birth form in a small subset of vessels with cerebellar predominance, while 
the vast majority of vessels remain normal as the developmental susceptibility can be 
focal and brain region specific. We provide an explanation that accounts for the 
experimental evidence and allows the two hit theory to function at all stages of life. 
These observations have important implications for the therapeutic approach to 
CCM disease. Currently the mainstay of therapy for CCM is surgical excision or 
radiological destruction of the lesion. Our previous work suggested that the genetically 
altered endothelium has increased activity of RhoA signaling that may be modified by 
therapy with the statin class of drugs (66). There are now several potential therapeutic 
approaches (67) suggested to modify the genetically altered endothelium of the CCM 
lesion, and it is hoped that a new era of medical management of CCM will prove 
beneficial. Here we suggest the potential of an additional therapeutic strategy to target the 
susceptible environment, thus protecting patients from the activation of underlying 
genetic susceptibilities. Antiangiogenic therapy may prove useful to prevent or delay 
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lesion formation or to stabilize the hemorrhage prone lesion. This strategy has already 
been proposed for other genetic vascular diseases, and the use of anti-VEGF therapy with 
bevacizumab is currently being tested in clinical trials for hereditary hemorrhagic 
telangiectasia (68). Additional environmental modifiers may also be found that form part 
of a multipronged medical approach to the treatment of CCM.  
 
3.5 Materials and Methods 
3.5.1 Mice 
 Mice with a conditional (floxed) allele for Ccm3 and a germline deleted Ccm3 
allele were generated previously. The endothelial inducible Cre recombinase used in this 
model (Pdgfb-iCreERT2) were used previously (50) and were originally obtained via 
Holger Gerhart (London Research Institute – Cancer Research UK, London, United 
Kingdom) from Marcus Fruttiger (University College London Institute of 
Ophthalmology, London, United Kingdon). Reporter mice expressing baseline red 
fluorescence with a Cre-inducible green fluorescence (Tomato-GFP mice) were obtained 
from Jackson Laboratories (Bar Harbor, ME).  
 
3.5.2 Reporter Gene Expression 
 Brain and intact eyes were prepared for cross-sectional analysis by embedding 
into OCT for frozen sections at 10 µm thickness. Sections were counterstained with 
DAPI and mounted with Dako Faramount Aqueous mounting media. Intrinsic 
fluorescence from tomato-red and GFP expression or from DAPI counterstain was 
detected using the Nikon AR1 confocal microscope using a 60X objective (with oil) 
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using NIS Elements software. 
 
3.5.3 Mouse MRI Studies 
 Both live and postmortem mouse brain MRI studies were performed as described 
previously (50). All MRI experiments were conducted on a 7T Bruker Biospec 70/30 
USR scanner (Bruker Biosin MRI Inc.) equipped with a BGA12S gradients set. A 
combination of volume-transmit-only radio frequency coil (internal diameter 72 mm) and 
a quad-surface-receive-only coil (internal diameter 1.5 cm) were used. For live scans, 
mice were anesthetized with 2.5% isoflurane and then placed into the scanner on top of a 
circulating heated water. During the scans, mice were monitored for temperature and 
respiration, with isoflurane concentration and water bath temperature adjusted to 
maintain a body temperature between 35.8 and 37.6 °C and respiration between 75 and 
100 breaths/minute. A gradient recalled echo sequence was used to acquire coronal slices 
spanning the whole brain. Sequence parameters were as follows: repetition time, 328 ms; 
echo time, 5.4 ms; flip-angle, 40°; 12 averages, in-plane-resolution 125 µm x 125 µm; 
and slice thickness 0.5 mm. For postmortem specimens, mouse skulls were fixed in 4% 
formaldehyde for at least 3 days before the brain was imaged with the skull intact. High 
resolution 3D gradient echo was acquired using the same scanner configuration described 
above, with isotopic voxel size of 78 µm x 78 µm x 78 µm over 9 hours. Other sequence 
parameters were as follows: repetition time, 250 ms; echo time, 7.5 ms; flip angle, 30°; 
and 2 averages. Two independent reviewers blinded to treatment group reviewed the MRI 
studies.  
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3.5.4 Retinal Processing 
 Eyes were enucleated and fixed overnight in 4% paraformaldehyde at 4 °C. 
Retinas were then dissected and stained with Alexa Fluor Isolectin GS-IB4 (Invitrogen). 
After staining, retinas were placed into PBS, cut four times to section the cup into 
leaflets, and then flat-mounted onto slides using Dako Faramount Aqueous mounting 
media. Images were acquired on a Nikon AR1 confocal microscope with a 10X objective 
and stitched into a 3x3 montage using the NIS Elements software. 
 
3.5.5 Viral Vectors Preparation and Transduction in the Mouse Brain 
 Adenoviral vectors with a CMV promoter driving Cre recombinase (Adeno-Cre) 
and control adenovector expressing green fluorescent protein (Adeno-GFP) were 
purchased from Vector Biolabs (Philadelphia, PA). Adeno-associated viral vectors 
containing vascular endothelial growth factor (AAV-VEGF) and ß-galactosidase (AAV-
LacZ) were prepared (69) by using a three plasmid cotransfection system. Briefly, 
recombinant pAAV plasmids were cotransfected with two helper plasmids to 293 cells 
using the calcium phosphate precipitate method. Two helper plasmids, one with 
adenoviral VA, E2A, and E4 regions and the other with the AAV rep and AAV serotype 
one cap genes (provided by Xiao Xiao, University of North Carolina), were cotransfected 
with AAV plasmids into HEK 293 cells to package the AAV vector.  Cell lysate was 
produced using three freeze-and-thaw cycles 3 days after the transfection. AAV vector 
was purified by CsCl2 centrifugation. Viral titers were determined by dot blot analysis of 
the DNA content.  
 Stereotactic injections of combination adenoviral and adeno-associated viral 
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vectors were performed as described previously (70). Following induction of anesthesia 
with isoflurane, the mice were placed in a stereotactic frame with a holder (David Kopf 
Instruments, Tujunga, CA), and a burr hole was drilled in the pericranium 2 mm lateral to 
the sagittal suture and 1 mm posterior to the coronal suture. A 3 µl viral suspension 
containing 2 x 107 plaque forming unit (PFU) adenoviral vectors and 2 x 109 genome 
copies (gcs) of AAV viral vectors were stereotactically injected into the right basal 
ganglia at a rate of 0.2 µl per minute using a Hamilton syringe. The needle was 
withdrawn after 10 minutes and the wound closed with a suture. 
 
3.5.6 Histologic and Fluorescent Stains 
 Following postmortem MRI, mouse brains were prepared and stained for H&E as 
described previously (50). Sections of brain were prepared at 5µm thickness, and H&E 
staining was performed according to classical protocols. Photomicrographs were obtained 
using a Zeiss Axiophot 2 microscope with 10x objective with an Axiocam HRc camera 
and Axiovision software. Sections were also stained for fluorescein-lycopersicin 
esculentum lectin (Vector Laboratories, Burlingame, CA). Two sections per mouse brain, 
1mm rostral and 1mm caudal of the injection site, were chosen. The angiogenic regions 
were imaged using a Lieca microscope with 10x objective and SPOT Camera and 
Software. Vessel diameters were analyzed using NIH Image 1.63 software  by observers 
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3.5.7 Genomic DNA Quantitative PCR for Copy Number 
 Paraffin sections of mouse brain were analyzed for Ccm3 gene copy number. 
Serial slides were analyzed for evidence of injection. Histologic stains were used on 
every fifth slide to define evidence of gliosis, or minimal injection injury. Bulk samples 
of brain tissue from the intervening sections were taken from the injected region for 
genomic DNA extraction using an Arcturus Veritas laser capture dissecting microscope 
to cut a standard pattern of five precise circular fields that were later scraped off of the 
slide with a scalpel into sample buffer. Images of the sections following tissue removal 
were obtained using the same system with a 2X objective. DNA was extracted using a 
Qiaquick PCR DNA extraction kit from Qiagen (Germantown, MD). A Ccm3 copy 
number assay sensitive to the known mutation induced by Cre recombinase was obtained 
from Applied Biosystems (Life Technologies, Grand Island, NY) and used for analysis of 
recombination efficacy. The assay was validated by comparison of DNA from control 














Figure 3.1. Late induction of gene deletion is insufficient for cavernous malformations. 
A. Tamoxifen treatment of Tomato-GFP;Pdgfb-iCreERT2 mice at weaning results in 
endothelial Cre activity within the brain and retina. Cavernous malformations form in the 
brains (B) and retina (C) of Ccm3flox/-;Pdgfb-iCreERT2 mice treated with tamoxifen at 










Figure 3.2. VEGF potentiates cavernous malformation development following the loss of 
Ccm3. A. H&E staining of mouse brain. Type 1 CCM lesions are apparent only from the 
brains of mice receiving both Cre recombinase and VEGF viral vectors. B. Lectin 
staining also identifies the lesions and allows quantification of vessel diameter. C. The 
combination of VEGF and Cre recombinase (group D) results in a population of 


















Figure 3.3. Viral vector driven expression of VEGF results in gliosis and edema 
independent of Cre expression. Mice given adeno-associated viral driven VEGF have 



























Figure 3.4. Viral vector driven expression of Cre recombinase results in equivalent gene 
deletion independent of VEGF expression. A. DNA was purified from a standard pattern 
of samples from the injected brain region. B. A Ccm3 gene copy number assay correctly 
identifies the copy number of control (Ccm3flox/flox and Ccm3flox/-) mice. Copy number is 




























Figure 3.5. Environmental and genetic synergy in CCM lesion formation. A. Two 
genetic hits at a developmentally vulnerable period is sufficient to induce CCM lesion 
formation. B. A second genetic hit that occurs later in life, outside of the developmentally 
vulnerable time window does not result in disease unless a subsequent environmental 
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 Endothelial cells are a critical component of the vascular system. These cells act 
in a monolayer and are responsible for regulation of transport and provide a barrier 
function. It is therefore critical to maintain the integrity of this monolayer during 
apoptotic challenge.  We sought to address the question of how endothelial cells manage 
apoptosis in order to protect the barrier. We demonstrate that endothelial cells use the 
process of cellular extrusion to remove an apoptotic cell from the monolayer without 
barrier disruption. We go on to show that this signaling mechanism used is based on an 
S1P-Rho axis, conserved across both the epithelium and the endothelium. Thus, our 
findings provide a mechanism for barrier preservation and open up potential avenues for 








 The vasculature is an essential system that delivers blood and nutrients throughout 
the body while also acting as a barrier between blood and the surrounding tissues.  This 
barrier is both physical, separating a fluid environment from a solid environment, as well 
as chemical, maintaining osmotic and nutrient balance in both areas (1).  Lining the 
vessels in a tight monolayer are endothelial cells, the key players in the regulation of 
vascular barrier function.  When barrier function is disrupted, fluid can leak into the 
surrounding tissues causing edema, inflammation, and tissue damage (2).  Several 
diseases are known to have a defective endothelial barrier.  One example is rheumatoid 
arthritis, where defects in cellular signaling and endothelial junctions leads to fluid leak 
into the synovial joints, where it causes swelling and inflammation (3). Another example 
can be found in cancer where tumors promote the growth of leaky vessels and allow for a 
greater rate of metastasis (4). Part of the problem presented in these situations comes 
from a direct threat on the endothelium.  Several insults, such as inflammatory cytokines 
or reactive oxygen species, bombard the endothelium and can induce apoptosis (5).  An 
apoptotic event can result in a compromised barrier as the cell surrenders its role in the 
monolayer and loses structural integrity.  Therefore, being able to strike a balance 
between managing barrier function and managing apoptosis is key in maintaining 
endothelial function.   
 Endothelial cells are not the only cells responsible for barrier function within the 
body. Epithelial cells also exact a similar role and work to form a barrier for the internal 
organs as well as the outside of the body. We previously found that epithelia maintain a 
constant barrier even when up to 40% of the cells comprising them die by a process 
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termed “cell extrusion” (6). To extrude a cell that is fated to die emits a lipid Sphingosine 
1-Phosphate (S1P), which binds the S1P receptor 2 (S1P2) in the neighboring cells, 
which trigger an actin and myosin II ring to form and contract around the cell, squeezing 
it out and simultaneously preventing any gaps that might have formed from the dying 
cell. Typically, epithelial cells die by first extruding alive and later dying due to loss of 
survival signaling from losing contact with the surrounding cells and matrix (7). 
However, apoptotic stimuli also triggers cells undergoing apoptosis to extrude early in 
the pathway before they lose membrane integrity (6, 8). Thus, epithelial extrusion 
successfully removes an apoptotic cell before it compromises the monolayer, preserving 
the barrier function. Consequently, we wondered if endothelia use a similar strategy that 
epithelia use to cope with cells dying within their ranks.  
 Here we demonstrate that apoptotic extrusion does occur in the endothelia. We 
found that endothelial cells in culture and in zebrafish embryos extrude cells targeted to 
die.  Furthering our study, we show that endothelial cells use an S1P-S1PR2-RhoA 
pathway to activate extrusion, indicating a conserved mechanism between epithelial and 
endothelia. Together this suggests the process of extrusion enables endothelia to keep a 
protective barrier as cells die and opens up a new avenue in studying vascular leak in the 
context of disease.  
 
4.4 Results 
4.4.1 Endothelia Extrude Apoptotic Cells 
 To investigate if extrusion occurs in the endothelium because the intrinsic rates of 
endothelial cell turnover is low, we investigated whether apoptotic stimuli cause 
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endothelial cells to extrude. We induced apoptosis in an endothelial monolayer by 
exposure to UV light. Human Umbilical Vein Endothelial Cells (HUVECs) grown on 
glass coverslips to confluence were exposed to UV-C to activate the intrinsic apoptotic 
pathway and culture for 2 hours. Immunofluorescence shows that HUVEC monolayers 
extruded active caspase-3-positive apoptotic cells, as an actin ring forms around and 
below them without any obvious gaps in the monolayer. While both untreated endothelial 
cells extruded cells, the number of extrusions greatly increased with UV-C treatment 
suggesting that, similar to epithelia, endothelia extrude cells during normal homeostatic 
turnover and in response to apoptotic stimuli (Figure 4.1A-D).  To confirm that the actin 
ring was actually contracting and that no gaps were produced as cells were extruded, we 
filmed HUVECs cells expressing LifeAct, a protein that labels filamentous actin.  Our 
movies indicate that as cells begin to die and contract, an actin ring forms in adjacent 
cells, which contracts around the dying cell to push it out of the monolayer 
(Supplemental Movie 1, Figure 4.1E).  Further, no gaps appear throughout this process, 
even when five cells have been extruded. Thus, endothelia extrude apoptotic cells by the 
same actin ring closure described in the epithelium. 
 
4.4.2 Barrier Function is Preserved After Induction of Apoptosis 
 While no gaps are apparent during the extrusion process in our films, to 
functionally test whether the barrier was preserved as cells die, we directly measured 
barrier function by electrical resistance. Even when 13% of the cells were measured to 
die by immunfluorescence (Figure 4.2A-F), the barrier function was maintained, as 
indicated by the high electrical resistance measured by Electric Cell-substrate Impedance 
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Sensing (ECIS). This technique allows for sensitive detection of any disruption to 
monolayer integrity, as when cell junctions were disrupted by either EGTA or by an 
adherens junction antibody, this resistance was lost (Figure 4.2G).  By contrast, both 
untreated cells and UV-C-exposed cells maintained their resistance up to 6 hours. 
Similarly, extruding epithelial monolayers treated with UV-C maintained high electrical 
impedence over a 6-hour period (Figure 4.2H). 
 
4.4.3 Endothelial Extrusion Requires S1P Signaling 
 Given that endothelia extrude dying cells, we next wondered if they use the same 
S1P-S1P2-Rho-dependent pathway identified for controlling epithelial cell extrusion. For 
an epithelial cell to extrude, it produces and emits S1P, which binds to S1P2, triggering 
the localized activation of Rho via the p115RhoGEF pathway (8, 9).  Blocking any step 
in this pathway leads to dying cells stuck within the monolayer and, eventually, the 
formation of epithelial gaps (6, 9) 
  In order to test if the endothelium uses the S1P-S1P2R-Rho pathway during 
extrusion, we treated endothelial monolayers with inhibitors at each step.  Inhibition of 
Rho with the downstream ROCK inhibitor Y27632 treatment causes up to a 90% 
reduction in successful extrusion in both nontreated and UV-C-treated HUVEC 
monolayers (Figure 4.3A).  Additionally, preventing the synthesis of S1P with a 
sphingosine-1-kinase inhibitor or preventing the interaction of S1P with S1P2 by using 
the S1PR2 specific agonist JTE-013 lead to a 60% decrease in successful extrusions 
(Figure 4.3C). Defective extrusion is indicated by sample images showing an 
uncontracted actin ring around a caspase-3-positive cell, where the DNA of the dying cell 
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lies in the same plane as the surrounding endothelial cell neighbors (Figure 4.3B,D).  
These data demonstrate that endothelial extrusion uses the same S1P-S1P2-RhoA 
pathway to trigger ring formation and closure as identified for epithelia. 
 
4.4.4 Extrusions Occur in Vivo 
 While we have observed endothelial cell extrusion in cultured endothelial 
monolayers, to be convinced of its physiological relevance, we needed to determine if 
endothelial cell extrusion occurs in vivo. To investigate if endothelia extrude in vivo, we 
turned to zebrafish embryos, which are translucent so that we can image cell movements 
live. Other model organisms lack developed vasculature or the ability to readily access 
cells for filming. Further, we have previously used zebrafish embryonic epidermis to 
follow epithelial cell extrusion live (8) due to how easy they are to visualize.  We chose 
to film the zebrafish common cardinal veins (CCVs), which develop in large flat 
endothelial sheets so that individual cells are easy to film and used the kdrl:GFP zebrafish 
line, which primarily labels the endothelium.  We targeted individual cells to die with an 
infrared laser and then followed their fate by imaging for the course of 8 hours.  Similar 
to videos of endothelial cell extrusion in culture, CCV endothelial cells targeted to die 
also extruded by cell contraction (Figure 4.4). Therefore, endothelia extrude cells targeted 
to die using the same signaling and mechanism described for epithelial cell extrusion.  
 
4.5 Discussion 
 Understanding how the endothelium can maintain a barrier function despite a 
continuous barrage of apoptotic stimuli is critical to understanding how diseases of 
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vascular leak can arise. Our work demonstrates that the endothelium can respond to 
apoptotic stress via a mechanism of cellular extrusion. Furthermore, we indicate a 
mechanistic overlap in extrusion signaling between endothelia and epithelia. The 
occurrence of this phenomenon suggests that extrusion, or the disruption of extrusion, 
may be a critical component to vascular disease and provides insight into S1P and Rho 
signaling.   
 S1P is known to regulate vascular development.  A knockout mouse model for 
S1PR2 shows vascular remodeling defects in the inner ear as well as neovascularization 
after hyperoxia (9, 10). RhoA also plays a critical role in the preservation of endothelial 
function and vascular development. For example, the disease Cerebral Cavernous 
Malformation (CCM), can present with a hyperactivation of RhoA and resulting vascular 
leak within the brain (11).  It is therefore possible that disruption of these signaling 
pathways can also disrupt endothelial extrusion, contributing to or giving rise to these 
disease states.  
 In addition, our work may inform the process of heamatopeosis. Previous work by 
Philipe Herbomels has described a similar phenomenon known as endothelial 
heamotpoetic transition. This is a process where endothelial cells bend and bud off from 
the aortic wall into the subaortic space, located on the basal side of endothelial cells (12). 
Directionality of extrusion has been described in the epithelia, with cells extruding either 
apically or basally. We have so far observed either apical or basal extrusion occurring 
singularly depending on the system. In cell culture this may be due to endothelial layers 
being far thinner than epithelial layers, biasing the cells to extrude apically.  While our 
observations in vivo are limited to basal extrusion, this is potentially influenced by the 
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curvature of the CCV. The inherent, flat architecture of endothelial cells may also 
contribute. Microtubules within the epithelial cells dictate extrusion direction by either 
contracting at the apical surface of the cell (basal extrusion) or by diving down to 
contract at the basal surface of the cell (apical extrusion) (8). It is therefore possible that 
endothelial cells are too planar for microtubule relocation.  
 Taken together, our results combined with the vast field of vascular leak suggest 
that endothelial extrusion may open up a new field of endothelial biology, and further 
study is required to examine how pervasive a role this concept has. 
 
4.6 Materials and Methods 
4.6.1 Zebrafish 
 Housing and experiments were conducted according to IACUC protocol. The 
zebrafish line kdrl:GFP was a gift from Brent Bisgrove.  Embryos were filmed starting 
between 20 and 22hpf for 8 hours while anesthetized with tricane.  Fish were mounted in 
1% low-melt agarose with  phenylthriourea.  
 
4.6.2 Cell Culture 
 Human Microvascular Endothelial Cells (HMVEC-d, Lonza CC-2543) and 
Human Umbilical Vein Cells (HUVEC, Lonza C2519A) were cultured according to 
manufacturer’s instructions. Madin Darby Canine Kidney Cells (MDCK II) and 
HEK293T cells were cultured in DMEM high glucose with 5% FBS and 100µg/mL 
penicillin/streptomycin (all from Invitrogen) according to manufacturer’s instructions.  
 




 Cells were grown to confluency on fibronectin-coated glass cover slips and fixed 
using 4% PFA at 37°C for 20 minutes.  Cells were then stained as previously described 
(Rosenblatt 2009) using Alexa Fluor 568 Phalloidin (Life Technologies A12380) at a 
1:100 dilution and Rabbit Anti-Active Caspase-3 (BD Pharmingen 559565) at a 1:1000 
dilution followed by Alexa Fluor 488 Anti-Rabbit (Life Technologies A11034) at a 1:100 
dilution. Cover slips were mounted using Prolong Gold Antifade Mountant with DAPI 
(Life Technologies P36930). 
 
4.6.4 Imaging 
 Fluorescent micrographs were taken using the Nikon AR1 microscope.  Visual 
quantification of cells was done using the Leica TCS SP5 microscope.  Live cell time-
lapse imaging was done using the Olympus IX81 automated microscope. Live imaging 
and IR ablations in zebrafish were done using the Prairie two-photon microscope. 
 
4.6.5 Barrier Function Assay 
 Cells were plated to confluency in a fibronectin-coated ECIS 8W10E+ gold 
electrode chamber slide (Biophysics).  Resistance across the monolayer was measured 
using the Electrical Cell-substrate Impedance System (ECIS) from Applied Biophysics.  
Cells were allowed to rest for 30 minutes prior to any treatment. Values were normalized 
against control and quantified.  
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4.6.6 Apoptosis Induction and Drug Inhibitors 
 To induce apoptosis via UV-C light, cells were placed into a UV Stratalinker 
1800 set to the Autocrosslink set at 400.  Inhibition of Rho was done using Y27632  
dihydrochloride (Tocris 1254) at a 200µM concentration. Inhibition of the S1P pathways 
was done using either 10µM JTE-013 (Tocris 2392) or 30µM SKI II (EMD 509106) prior 






























Figure 4.1. Extrusion occurs in the endothelium.  A-D. Fluorescent micrographs of an 
endothelial cell undergoing extrusion. The actin ring can be seen, as labeled with 
phalloidin (A), closing around a dying cell, as indicated by both active caspase staining 
(B) and condensed nuclei (C, DAPI). The final panel is a merged image with phalloidin 
in red, caspase in green, and nuclei in blue. E. Still images taken from a timelapse 




















Figure 4.2. Endothelial and epithelial barrier function is maintained during apoptotic 
stress. A-F. Fluorescent images of apoptosis in an endothelial monolayer. As indicated by 
nuclear (DAPI, blue; A,D) and caspase (green; B,E) staining. (C,F) are a merged image. 
G. Quantification of apoptosis as determined by relative fluorescence of caspase staining. 
H. Transendothelial measurement of resistance, an indicator of barrier function. UV-
exposed endothelial cells are able to maintain resistance. Cadherin-5, functional blocking 
antibody, was used to control for junction disruption. EGTA was used as a positive 
control. I. The epithelial cell-line, MDCK, displays similar patterns of resistance to that 











Figure 4.3. Endothelial extrusion uses the S1P-S1P2R-Rho pathway. A,B. Cells treated 
with Y27632 or sphingosine kinase inhibitor treated remain stuck in the monolayer C,D. 
Cells were stained for actin (red), caspase (green), and nuclei (DAPI, blue). E. 
Quantification of Y27632 (50uM) and sphingosine kinase (30uM) inhibitor treated 













Figure 4.4. Endothelial extrusion occurs in vivo. A. Still images taken from a timelapse 
recording of a developing CCV in zebrafish with endothelial cells undergoing extrusion. 
B. Close up of an extrusion still. White arrows indicate neighboring cells while the green 
arrow indicates cell mid-extrusion. C. Table quantifying the number extrusions per live 
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 Taken together, the work presented in this dissertation provides advancements in 
the fields of Cerebral Cavernous Malformation and endothelial cell biology. First, using a 
novel mouse model of CCM, we describe the early morphological onset of CCM lesions 
within the retina and present two novel defects, the first being endothelial hypersprouting 
in the retina, which precedes lesion formation, and the second being an impaired 
endothelial response to flow. Both inform us about the initial defects that contribute to 
lesion formation and focus on primary disease cause rather than on later effects. Second, 
we go on to demonstrate that a second genetic hit is not adequate for adult lesion onset 
and that an additional environmental hit is needed. In conjunction with our finding that 
lesions develop in a stereotypical pattern, this calls into question the two-hit hypothesis in 
CCM. Finally, we go on to examine barrier function and define the existence of 
endothelial cellular extrusion, which could potentially be a contributing factor to the leak 
observed in CCM.  
 Several questions remain to be addressed as each chapter has opened up new 
directions to be investigated.  Questions remain as to the exact mechanism responsible for 
the impaired flow response and the signaling cascades disrupted during 
angiomorphogenesis.  Determining if there is a minimum or maximum flow rate 
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threshold that cells respond to would provide insight into arteriovenous differentiation. In 
addition, changes in the downstream signaling upon flow stimulation needs to be studied, 
for example, changes in proliferation or apoptosis.   Furthermore, work needs to be done 
to determine if response to flow can be influenced by environmental factors, or vice 
versa.  Determining which environmental factors can lead to adult CCM onset is also a 
question open for investigation as several pathways have been implicated in CCM 
pathogenesis. How these pathways interconnect and whether the resulting defects, such 
as vascular leak, could contribute to the environmental hits associated with late onset 
disease remains to be seen. Lastly, could defective endothelial extrusion contribute to the 
formation of CCM?  Rho signaling is critical for extrusion, considering that Rho is 
dysregulated when CCM2 is lost, which suggests that the barrier function provided by 
extrusion could be disrupted in the disease. More work is needed to determine if loss of 
the CCM genes disrupts the process of extrusion and if that contributes to vascular leak.  
In the end, each of these studies is a reminder that rarely is a disease ever a symptom of a 
singular, concrete defect. Rather, diseases arise from a defect that cascades into other 
defects until a single stream has flooded into an ocean.  
	  
